» Articles » PMID: 38275868

Radiation Exposure from GEP NET Surveillance

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2024 Jan 26
PMID 38275868
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Neuroendocrine tumors (NET) are neoplasms that secrete peptides and neuroamines. For gastroenteropancreatic (GEP) NET, surgical resection represents the only curative option. Ten-year imaging surveillance programs are recommended due to long time-to-recurrence following resection. We performed retrospective chart review evaluating radiation exposure and practice patterns from surveillance of completely resected GEP NET.

Methods: We performed a retrospective cohort study of cases with well-differentiated GEP NET from January 2005 to July 2020. Location of primary, modality of imaging, and duration of follow-up were collected. Dosimetry data was collected to calculate effective dose.

Results: 62 cases were included with 422 surveillance scans performed. Cross-sectional imaging was used in 82% and functional imaging was used in 18% of scans. Mean number of scans per year was 1.25 (0.42-3). Mean total effective dose was 56.05 mSv (SD 45.56; 0 to 198 mSv) while mean total effective dose per year was 10.62 mSv (SD 9.35; 0 to 45 mSv). Over the recommended ten years of surveillance the estimated total effective dose was 106 mSv.

Conclusions: Surveillance of completely resected GEP NET results in cumulative radiation doses in the range associated with secondary malignancy development. Strategies to minimize radiation exposure in surveillance should be considered in future guideline development.

References
1.
Walker R, Smith G, Liu E, Moore B, Clanton J, Stabin M . Measured human dosimetry of 68Ga-DOTATATE. J Nucl Med. 2013; 54(6):855-60. PMC: 4472480. DOI: 10.2967/jnumed.112.114165. View

2.
Deak P, Smal Y, Kalender W . Multisection CT protocols: sex- and age-specific conversion factors used to determine effective dose from dose-length product. Radiology. 2010; 257(1):158-66. DOI: 10.1148/radiol.10100047. View

3.
Lee K, Lee S, Park J, Lee S, Kim H, Lee W . Risk of Hematologic Malignant Neoplasms From Abdominopelvic Computed Tomographic Radiation in Patients Who Underwent Appendectomy. JAMA Surg. 2021; 156(4):343-351. PMC: 8047726. DOI: 10.1001/jamasurg.2020.6357. View

4.
Pavel M, Oberg K, Falconi M, Krenning E, Sundin A, Perren A . Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 31(7):844-860. DOI: 10.1016/j.annonc.2020.03.304. View

5.
Shah M, Goldner W, Benson A, Bergsland E, Blaszkowsky L, Brock P . Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021; 19(7):839-868. DOI: 10.6004/jnccn.2021.0032. View